CLK Sensitivity Biomarker for Imidazopyridine Solid Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments with imidazo[4,5-b]pyridine derivatives for solid cancers lack the ability to predict therapeutic efficacy, making it difficult to identify subjects who will benefit most from these treatments.
Innovation Solution
A method for predicting therapeutic response to imidazo[4,5-b]pyridine derivatives in solid cancers by detecting genetic characters such as MYC gene amplification, mutation, or chromosomal transposition, and other gene alterations using techniques like array comparative genomic hybridization and next-generation sequencing, to determine subjects' sensitivity to CLK inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If imidazo[4,5-b]pyridine derivatives are used to treat solid cancers, then antitumor activity is achieved, but the ability to predict therapeutic efficacy is lacking
Solution Approach 1:
The patent applies preliminary action by detecting genetic characters (MYC gene amplification, mutation, chromosomal transposition) before treatment to predict therapeutic response. This allows identification of subjects likely to benefit from imidazo[4,5-b]pyridine derivative treatment, enabling proactive selection of appropriate candidates rather than waiting for treatment outcomes.
2Measurement precision
If genetic character detection methods are implemented, then subject identification accuracy is improved, but diagnostic complexity increases
Solution Approach 1:
The patent extracts specific genetic characters (MYC gene amplification, mutation, chromosomal transposition) as predictive biomarkers from the complex genomic landscape. By focusing on these particular genetic alterations rather than analyzing the entire genome, the method achieves accurate responsivity prediction while reducing diagnostic complexity compared to comprehensive genomic profiling.
Data Source
AI summary
Provided is a means to predict the anticancer therapeutic efficacy of 1-((5-(1R)-1-fluoroethyl)-1,3,4-oxadiazol-yl)methyl)-6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-1H-imidazo[4,5-b]pyridine or a derivative thereof in solid cancer and thereby specifying a subject who will be the most benefitted from treatment with the compound and treatment with the compound in combination with another drug and/or another therapy. As a biomarker for predicting therapeutic response to the compound, a genetic character predicted to impart sensitivity to CLK inhibition is used.